Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SARS-CoV-2 plasma Clear all
Completed Early Phase 1 Interventional

CoVID-19 Plasma in Treatment of COVID-19 Patients

NCT04355897
View directory record Official record
Conditions
COVID 19
Interventions
Convalescent COVID 19 Plasma
Biological
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Wichita, Kansas • Syracuse, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 1 Interventional Results available

COVID-19 Convalescent Plasma for Mechanically Ventilated Population

NCT04388527
View directory record Official record
Conditions
Covid-19
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 8, 2026, 5:02 AM EDT
Withdrawn Phase 1 Interventional

Intermediate IND Severe Illness COVID-19 CP

NCT04411602
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome, COVID
Interventions
SARS-CoV-2 plasma
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Novi, Michigan • Southfield, Michigan • Warren, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Results available

Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults

NCT04362176
View directory record Official record
Conditions
COVID-19, Coronavirus, SARS-CoV-2
Interventions
pathogen reduced SARS-CoV-2 convalescent plasma, Placebo
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Little Rock, Arkansas • La Jolla, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 8, 2026, 5:02 AM EDT
Completed No phase listed Observational

Immune Responses to COVID-19 Infection or Vaccination

NCT05379478
View directory record Official record
Conditions
COVID-19
Interventions
Laboratory assessment of antibody profiles
Diagnostic Test
Lead sponsor
Aditxt, Inc.
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients

NCT04364737
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infection
Interventions
Convalescent Plasma, Saline solution
Biological · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
New Haven, Connecticut • Miami, Florida • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 8, 2026, 5:02 AM EDT
Terminated Phase 2 Interventional Results available

Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

NCT04513158
View directory record Official record
Conditions
Covid19
Interventions
Convalescent Plasma
Biological
Lead sponsor
Joseph M. Flynn, D.O., MPH
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 8, 2026, 5:02 AM EDT
No Longer Available No phase listed Expanded access

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

NCT04360486
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Anti-Sars-CoV-2 Convalescent Plasma
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
U.S. locations
26
States / cities
Oceanside, California • San Diego, California • Fort Carson, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 2 Interventional

AT1001 for the Treatment of Long COVID

NCT05747534
View directory record Official record
Conditions
Long COVID, Long COVID-19, Post Acute COVID-19 Syndrome, Post Acute Sequelae of COVID-19
Interventions
Larazotide Acetate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 50 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 8, 2026, 5:02 AM EDT
Terminated Phase 3 Interventional Results available

VA CoronavirUs Research and Efficacy Studies-1

NCT04539275
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma, Masked Saline Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Sep 8, 2026, 5:02 AM EDT
Not listed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

NCT04469179
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal Saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Not applicable Interventional Results available

Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers

NCT04334876
View directory record Official record
Conditions
SARS-CoV-2
Interventions
SARS-CoV-2 IgG Antibody Testing Kit
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Plasma Adsorption in Patients With Confirmed COVID-19

NCT04358003
View directory record Official record
Conditions
Respiratory Failure, ARDS
Interventions
Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
Device
Lead sponsor
Marker Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Little Rock, Arkansas • Albuquerque, New Mexico • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 8, 2026, 5:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Collection of Anti-SARS-CoV-2 Immune Plasma

NCT04344977
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Torrance, California • Miami, Florida • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 8, 2026, 5:02 AM EDT
Terminated Phase 2 Interventional Results available

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

NCT04343755
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma
Biological
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)

NCT04554992
View directory record Official record
Conditions
Covid19
Interventions
COVID 19 Convalescent Plasma
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 8, 2026, 5:02 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

COVID-19 Diagnostic Self-testing Using Virtual Point-of-care

NCT04348864
View directory record Official record
Conditions
Communicable Disease, COVID-19, Sars-CoV2, Infectious Disease, Coronavirus, Virus
Interventions
COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support, Telemedicine
Diagnostic Test · Other
Lead sponsor
Neuroganics LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Sep 8, 2026, 5:02 AM EDT
Not listed No phase listed Observational

Change in Antibody Levels Following SARS-CoV-2 (Covid-19) Vaccinations

NCT04944095
View directory record Official record
Conditions
Covid-19, Subjects Vaccinated Against Covid-19
Interventions
Change in SARS-CoV-2 Antibody Levels
Other
Lead sponsor
Dr. Sidney J. Stohs
Other
Eligibility
55 Years and older
Enrollment
10,000 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
Southlake, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Sep 8, 2026, 5:02 AM EDT
Terminated Phase 3 Interventional

MSCs in COVID-19 ARDS

NCT04371393
View directory record Official record
Conditions
Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
Interventions
Remestemcel-L, Placebo
Biological · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 8, 2026, 5:02 AM EDT
Completed No phase listed Observational Results available

Evaluation of Point-of-Care (EPOC) for COVID-19

NCT05227404
View directory record Official record
Conditions
COVID-19, SARS CoV 2 Infection
Interventions
LumiraDX, RightSign, Case Control
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 8, 2026, 5:02 AM EDT
Completed No phase listed Observational

An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients

NCT04471051
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of MAS825 in Patients With COVID-19

NCT04382651
View directory record Official record
Conditions
COVID-19 Pneumonia, Impaired Respiratory Function
Interventions
MAS825, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Chula Vista, California • Glendale, California • Irvine, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 8, 2026, 5:02 AM EDT